
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending June 24, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending June 17, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending June 10, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending June 3, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 27, 2022.
The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 20, 2022.
Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.
Interim data from the phase 2 Skyline trial demonstrated a 62.5% response rate.
Review top news and interview highlights from the week ending May 13, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 6, 2022.
Investigators presented up to 2 years of post-marketing data on the first-ever gene therapy.
Updated data at ARVO show that AGTC-501 had sustained efficacy and safety at 18 months for patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Veeral S. Sheth, MD, MBA, Director of Clinical Research at the University of Retina and Macula Associates, discusses advanced therapies for retinal diseases.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
New data from cohort 4 showed outer retinal restoration following treatment with OpRegen.
The post-hoc analysis of the OPTIC trial explored the effects of neutralizing antibodies on patients treated with ADVM-002.
Review top news and interview highlights from the week ending April 29, 2022.